CRISPR, crispr genome editing system - Part 4

The billion-dollar CRISPR patent battle: A case of big money shaping science

crispr money
The 21st century is still young, but it may already have its era-defining patent fight. The contestants are the University of California and the Broad Institute, a Harvard- and MIT-affiliated research foundation endowed by Los Angeles billionaire Eli Broad. At stake are the rights to a breakthrough gene-editing technology known as CRISPR — and more precisely, to billions of dollars in royalties and license fees likely to flow to whichever claimant prevails before the U.S. Patent and Trademark Office (and in the almost inevitable appeals in court). “This is a monumental event for patent attorneys, molecular biologists, the PTO, and the world,” patent expert Jacob Sherkow wrote recently on Stanford’s Law and Biosciences blog. CRISPR — an acronym for the...
Read More..

CRISPR may be used for oil production through the yeast with edited genome

RIVERSIDE, Calif. ( — A team led by a researcher at the University of California, Riverside has adapted the CRISPR-Cas9 gene editing system for use in a yeast strain that can produce useful lipids and polymers. The development will lead to new precursors for biofuels, specialty polymers, adhesives and fragrances. Published recently in the journalACS Synthetic Biology, the research involves the oleaginous (oil-producing) yeast Yarrowia lipolytica, which is known for converting sugars to lipids and hydrocarbons that are difficult to make synthetically. Until now, Y. lipolytica has been hard to manipulate at the genetic level, but the application of CRISPR-Cas9 will change that, allowing scientists to tap into its bio-manufacturing potential. Described in 2012, CRISPR-Cas9 is a groundbreaking technique that...
Read More..

British researchers starts to genetically modify human embryos

crispr human
Scientists investigating miscarriage will not be able to implant embryos or study them for more than two weeks, says HFEA Britain’s first genetically modified human embryos could be created within months, after scientists were granted permission by the fertility regulator to carry out the procedure. The Human Fertilisation and Embryology Authority (HFEA) regulator approved a licence application by Kathy Niakan, a stem cell scientist at the Francis Crick Institute in London, to perform so-called genome editing on human embryos. The decision permits Niakan to study the embryos for 14 days for research purposes only. It does not permit them to be implanted into women. Niakan’s research is aimed at finding the genes at play in the early days of human...
Read More..

CRISPR Used To Repair Blindness-Causing Gene Defect

Hailed as a breakthrough with the potential to correct genetic mutations and cure life-threatening diseases, the gene editing platform CRISPR/Cas9 may also be able to reverse an inherited condition that causes blindness. Scientists at the Columbia University Medical Center and University of Iowa used CRISPR to repair a genetic mutation responsible for retinitis pigmentosa in induced pluripotent stem cells derived from a patient with the disease. Retinitis pigmentosa is a genetic eye condition that causes the retina to deteriorate, leading to a slow loss of vision and resulting in blindness in at least 1.5 million cases worldwide. There is no cure for retinitis pigmentosa, and the only treatment is vitamin A, which may help slow down the progression of vision loss in...
Read More..

New Gene Editing Technology Promises Most Monumental Advance of Humankind Into the Future

By Dr. Mercola In his 1932 sci-fi novel “Brave New World,” Aldous Huxley explored what life might be like in AD 2540 — a world in which children are born in government owned baby hatcheries. In his world, human freedom is virtually non-existent, as each individual is genetically engineered and psychologically conditioned to fulfill a specific role within one of the five societal classes. Over 500 years before his prediction, we’re already seeing the germination of some of his projections. The technical development that is taking medicine by storm is CRISPR (clustered regularly interspaced short palindromic repeat) — a gene editing tool that has the most profound potential to change the health world as we know it that I have...
Read More..

Editas Aims For $100M CRISPR IPO

crispr cas investment
Editas Medicine is pushing ahead with plans to go public. An IPO for the Cambridge, MA-based company would make it the first among the handful of biotechs that are betting on the groundbreaking CRISPR-Cas9 gene editing system to develop human therapeutics. In a regulatory filing posted today, Editas said it would aim to sell 5.9 million shares in the $16 to $18 range. The midpoint of that range would add up to a $100 million IPO and leave the company, for the moment, with a market value just north of $600 million. If all goes well, bankers could sell extra shares and bump the deal total to $122 million. Though the blizzard that just buried the East Coast largely spared...
Read More..

U.S. researchers improve CRISPR gene editing technique

SAN FRANCISCO, Jan. 20 (Xinhua) — Researchers at University of California, Berkeley, have improved CRISPR-Cas9 technology and achieved a success rate of 60 percent when replacing a short stretch of DNA with another. The advance in CRISPR, short for clustered regularly interspaced short palindromic repeats, using the Cas9 protein is useful when trying to repair genetic mutations that cause hereditary diseases, such as sickle cell disease or severe combined immune deficiency. The study at the university on the U.S. west coast about gene editing, a major biotech research area in recent years, is published in the Jan. 21 issue of the journal Nature Biotechnology. “The exciting thing about CRISPR-Cas9 is the promise of fixing genes in place in our genome,...
Read More..

Crispr goes commercial: Genetic goldrush

crispr cas investment
Within just three years since the discovery of its gene-editing potential, the new technique Crispr has become the hottest, and most controversial, development in genomics research. And now it’s more than just a science – it’s big business too. First discovered in bacteria, Crispr (clustered regularly interspaced short palindromic repeats) is a genome-editing tool that can target specific genes in any organism based on RNA–DNA base pairing and then precisely cut the gene through the activities of the enzyme known as Crispr-associated protein 9 or Cas9. The technology can delete, repair or replace genes, and is faster, easier, cheaper and – in principle – more precise than other gene-editing techniques. With potential benefits across human health, agriculture and industrial biotechnology,...
Read More..

Molecular biology meets computer science tools in new system for CRISPR

Nicolo Fusi is one of the researchers who collaborated on the new CRISPR tools A team of researchers from Microsoft and the Broad Institute of MIT and Harvard has developed a new system that allows researchers to more quickly and effectively use the powerful gene editing tool CRISPR. The system, unveiled Monday and dubbed Azimuth, uses machine learning, in which a computer takes a limited set of training data and uses that to learn how to make predictions about data it hasn’t yet seen. In this case, the machine learning system is being used to predict which part of a gene to target when a scientist wants to knockout – or shut off – a gene. Machine learning enables the...
Read More..

Controversial CRISPR history sets off an online firestorm

crispr invesment
It isn’t often that biology finds itself in the same galaxy of the Twitterverse as, say, “The Bachelor,” but on Tuesday morning CRISPR did. The trending topic was sparked by a recent “Perspective” in Cell limning the history of the gene-editing technique. But this history was loaded, as history often is. CRISPR’s history could determine the outcome of a bitter patent fight worth many millions of dollars, and this version was written by the director of the institute that stands to reap some of those millions. The essay has triggered a deep controversy over disclosing conflicts of interest and the close ties between journals and certain research groups. CRISPR is a tool that acts as a microscopic pair of scissors with the ability to slice DNA. The Perspective’s author, Eric Lander, is president...
Read More..